LAMELLASOME™ Platform Technologies
Lamellar bodies have an integral role in maintaining a healthy physiological balance throughout the body. LAMELLASOME™ technology has been synthetically engineered to mimic native Lamellar bodies optimising their characteristics for specific therapeutic purposes. As a result, LAMELLASOME™ now forms a range of patented platform technologies across chronic fibrosis, anti-infectives, and a targeted therapeutic approach to serious rare diseases. Within each platform lies the potential to create multiple treatments tailored to address specific medical needs, improving efficacy and reducing side effects.
LAMELLASOME™ Anti-fibrotic Platform
These products disrupt the progression of fibrosis, the key pathology of progressive pulmonary fibrosis.
LAMELLASOME™ Anti-infective Platform
These products are designed to tackle serious bacterial infection and the global crisis of antimicrobial resistance.
LAMELLASOME™ Rare Disease Platform
These products advance novel treatments for rare diseases where there is high unmet clinical need.
Lamellar Biomedical are pioneering product development using their proprietary LAMELLASOME™ technology in therapeutic applications that utilise the differing LAMELLASOME™ platform capabilities. The initial focus is on developing a portfolio of products, each with a significant impact on their respective therapeutic area.
Strategic out-licensing, co-development and partnering
Lamellar would welcome strategic discussions to further advance development programs.